Authors

Roy Chemaly, MD, MPH, MD Anderson Cancer Center

Roy Chemaly, MD, The University of Texas MD Anderson Cancer Center

Roy Decker MD, PhD

Latest:

Dr. Decker on Pembrolizumab With Concurrent Chemoradiotherapy in Inoperable Locally Advanced NSCLC

Roy H. Decker, MD, PhD, discusses the use of pembrolizumab with concurrent chemoradiotherapy in patients with inoperable, locally advanced non–small cell lung cancer.

Roy Herbst, MD

Latest:

Dr. Herbst on Considerations for Frontline Immunotherapy in NSCLC

Roy S. Herbst, MD, PhD, discusses considerations for frontline immunotherapy in non–small cell lung cancer.

Roy Herbst, MD, PhD, Yale Cancer Center

Latest:

Perioperative Approaches to NSCLC

Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.

Roy Herbst, MD, Yale School of Medicine

Roy S. Herbst, MD, PhD

Latest:

Managing AEs With Osimertinib

Panelists discuss how managing adverse events (AEs) with osimertinib requires proactive monitoring and intervention, with monotherapy generally being well-tolerated aside from common AEs like rash and diarrhea.

Roy S. Herbst, MD, PhD, Yale

Roy S. Herbst, MD, PhD, Yale Cancer Center

Latest:

Immunotherapy for NSCLC: Clinical Pearls

Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.

Roy S. Herbst, MD, PhD, Yale School of Medicine

Roy Weiner, MD

Latest:

Dr. Roy Weiner on the Importance of Diversity in Cancer Research

Roy Weiner, MD, Associate Dean for Clinical Research and Training Associate Director of Clinical Research for Tulane Cancer Center discusses the importance of racial and ethnic diversity in cancer research.

Rozita Yarmand, PhD

Latest:

Addressing Unmet Needs in Medullary Thyroid Cancer

Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses unmet needs in medullary thyroid cancer.

Ruben A. Mesa, MD

Latest:

Myeloproliferative Neoplasm Management: Future Directions in Care

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.

Ruben A. Mesa, MD, FACP, Mayo Clinic Cancer Center

Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center

Latest:

Bone Marrow Transplant for Patients With MF

Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.

Ruben Mesa, MD

Latest:

Overview on Essential Thrombocythemia and Polycythemia Vera Management

Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.

Ruben Mesa, MD, Mayo Clinic

Ruben Mesa, MD, UT Health San Antonio Cancer Center

Latest:

Dr. Mesa on the Rationale for the MOMENTUM Trial in Myelofibrosis

Ruben A. Mesa, MD, discusses the rationale for the phase 3 MOMENTUM study in myelofibrosis.

Ruben Niesvizky, MD

Latest:

Dr. Niesvizky on Sequencing Therapies for Patients With Multiple Myeloma

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses sequencing agents for patients with multiple myeloma.

Rudi Ross, BS, CCRC

Latest:

Changes in Prostate Cancer Presentation for Radiation Oncology Care

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.